P548: Limited clinical value in assessing the distribution of endoscopic disease activity in patients with ulcerative colitisECCO '18 Vienna
2018
P549: Systemic cytomegalovirus infection is a relevant factor affecting short- and long-term outcomes of patients with acute severe ulcerative colitis: An 11-year experienceECCO '18 Vienna
2018
P550: Early 12-week ultrasound response to treatment, used as a predictor of response at 6 months in Crohn’s disease: A prospective cohort studyECCO '18 Vienna
2018
P551: 6-Thioguanine nucleotide levels are associated with mucosal healing in patients with Crohn’s disease: A multi-centre, international studyECCO '18 Vienna
2018
P552: Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisationECCO '18 Vienna
2018
P553: Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of golimumabECCO '18 Vienna
2018
P554: Incidence and impact of immunogenicity in a randomised, double-blind phase III study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximabECCO '18 Vienna
2018
P555: Coagulation disorders in a population of patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P556: Cyclosporine in acute severe steroid-refractory ulcerative colitis: Short-and long-term outcomesECCO '18 Vienna
2018
P557: Cost-effectiveness of infliximab vs. surgery for severe chronic ulcerative colitis: a Markov analysisECCO '18 Vienna
2018
P558: Golimumab improves patient-reported work productivity and activity impairment in patients with ulcerative colitis: Interim results from a non-interventional trial in GermanyECCO '18 Vienna
2018
P560: Granulocyte–monocyte apheresis combination therapy after loss of response to anti-TNF drugsECCO '18 Vienna
2018
P561: A comparison of medication adherence and persistence between intravenous biologics and oral small-molecule therapiesECCO '18 Vienna
2018
P562: Role, efficacy and safety of budesonide multi-matrix in ulcerative colitis in real life: A study in three Italian third-level centresECCO '18 Vienna
2018
P563: Stopping anti-TNFα monotherapy in Crohn's disease patients in deep remission and favourable disease characteristics is associated with a high rate of relapseECCO '18 Vienna
2018
P564: Indigo naturalis induces mucosal healing in patients with ulcerative colitis: A multicentre randomised controlled trialECCO '18 Vienna
2018
P565: Real-world use of azathioprine metabolites changes clinical management of inflammatory bowel diseaseECCO '18 Vienna
2018